H-SER-LEU-LEU-LYS-NH2
| 中文名稱 | H-SER-LEU-LEU-LYS-NH2 |
|---|---|
| 中文同義詞 | SLLK,TSP1抑制劑控制肽;對照肽H-SER-LEU-LEU-LYS-NH2 |
| 英文名稱 | H-SER-LEU-LEU-LYS-NH2 |
| 英文同義詞 | H-SER-LEU-LEU-LYS-NH2;SLLK, Control Peptide for TSP1 Inhibitor;SLLK;SLLK-NH2;L-Lysine, L-seryl-L-leucyl-L-leucyl-;L-Seryl-L-leucyl-L-leucyl-L-lysine;Control Peptide for TSP1 Inhibitor |
| CAS號 | 464924-27-4 |
| 分子式 | C21H41N5O6 |
| 分子量 | 459.58 |
| EINECS號 | |
| 相關類別 | 多肽;標準品;目錄多肽;peptide |
| Mol文件 | Mol File |
| 結構式 |  |
H-SER-LEU-LEU-LYS-NH2 性質
| 沸點 | 815.4±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.164±0.06 g/cm3(Predicted) |
| 儲存條件 | -15°C |
| 酸度系數(shù)(pKa) | 3.31±0.10(Predicted) |
SLLK, Control Peptide for TSP1 Inhibitor 是 LSKL 的對照肽。
TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). mRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides. Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice.